CAS OpenIR  > 生化工程国家重点实验室
Orlistat response to missense mutations in lipoprotein lipase
Chen, Huayou1,2,3; Jia, Jinru1; Ni, Zhong1; Vastermark, Ake3; Wu, Bangguo1; Le, Yilin1; Jawad, Ullah1
2017-07-01
Source PublicationBIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
ISSN0885-4513
Volume64Issue:5Pages:464-470
Abstract

The human lipoprotein lipase (LPL) is a therapeutic target for obesity, and inhibition of LPL with the approved small molecule agent orlistat has been widely used in clinic to treat obesity-related health problems such as diabetes and cardiovascular diseases. However, a variety of missense mutations in LPL protein have been observed, which may cause resistance or sensitization for orlistat, largely limiting the clinical applications of orlistat in obesity therapy. Here, we integrated molecular dynamics simulations and enzyme inhibition to investigate orlistat response to 16 disorder-associated missense mutations in LPL catalytic domain. It was found that most mutations have a modest effect on orlistat binding, and only few can exert strong impact to the binding. Three unfavorable (Trp86Arg, Ile194Thr, and Glu242Lys) and two favorable (His136Arg and Gly188Glu) mutations were identified, which can alter the binding affinity and inhibitory activity of orlistat considerably. Structural and energetic analysis revealed that these potent mutations induce orlistat resistance and sensitization by directly influencing the intermolecular interaction between LPL and orlistat or by indirectly addressing allosteric effect on LPL structure. (C) 2016 International Union of Biochemistry and Molecular Biology, Inc.

KeywordLipoprotein Lipase Orlistat Missense Mutation
SubtypeArticle
WOS HeadingsScience & Technology ; Life Sciences & Biomedicine
DOI10.1002/bab.1500
Indexed BySCI
Language英语
WOS KeywordFamilial Lpl Deficiency ; Monoacylglycerol Lipase ; Atomic Charges ; Plasma-lipids ; Gene ; Tetrahydrolipstatin ; Atherosclerosis ; Inhibitors ; Disease ; Patient
WOS Research AreaBiochemistry & Molecular Biology ; Biotechnology & Applied Microbiology
WOS SubjectBiochemistry & Molecular Biology ; Biotechnology & Applied Microbiology
Funding OrganizationOpen Funding Project of the National Key Laboratory of Biochemical Engineering ; National Key Basic Research Program (973 Program) of China(2011CBA00800) ; Key Agriculture Support Project of Jiangsu Province, China(BE201340) ; National Natural Science Foundation of China(31200602)
WOS IDWOS:000408126800002
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ipe.ac.cn/handle/122111/23149
Collection生化工程国家重点实验室
Affiliation1.Jiangsu Univ, Inst Life Sci, 301 Xuefu Rd, Zhenjiang 212013, Peoples R China
2.Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing, Peoples R China
3.Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA
Recommended Citation
GB/T 7714
Chen, Huayou,Jia, Jinru,Ni, Zhong,et al. Orlistat response to missense mutations in lipoprotein lipase[J]. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY,2017,64(5):464-470.
APA Chen, Huayou.,Jia, Jinru.,Ni, Zhong.,Vastermark, Ake.,Wu, Bangguo.,...&Jawad, Ullah.(2017).Orlistat response to missense mutations in lipoprotein lipase.BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY,64(5),464-470.
MLA Chen, Huayou,et al."Orlistat response to missense mutations in lipoprotein lipase".BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY 64.5(2017):464-470.
Files in This Item:
File Name/Size DocType Version Access License
Orlistat response to(542KB)期刊论文出版稿限制开放CC BY-NC-SAApplication Full Text
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Chen, Huayou]'s Articles
[Jia, Jinru]'s Articles
[Ni, Zhong]'s Articles
Baidu academic
Similar articles in Baidu academic
[Chen, Huayou]'s Articles
[Jia, Jinru]'s Articles
[Ni, Zhong]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Chen, Huayou]'s Articles
[Jia, Jinru]'s Articles
[Ni, Zhong]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.